Core--Molecular Laboratory

核心--分子实验室

• 批准号: 7287732
• 负责人: BARBARA A ZEHNBAUER
• 金额: $ 5.72万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7287732
• 关键词: artificial chromosomes; biomedical facility; molecular oncology; neoplasm /cancer; neoplasm /cancer genetics; nucleic acid sequence; polymerase chain reaction; southern blotting

The Molecular Core Laboratory (MCL) of the $iteman Cancer Center is a shared resource facility that provides molecular pathology services to both basic research and clinical research studies. The mission of the MCL is to rapidly translate basic research observations to new diagnostic and/or prognostic clinical molecular tests. The MCL works with researchers to develop and implement molecular biology assays to analyze mutations and aberrant gone expression in human malignancies, The methods utilized in the MCL range from the routine (genomic Southern analysis, PCR screening, DNA sequencing) to project-specific techniques (BAC probes, protein truncation test, telomere length). New projects frequently require adaptation and optimization of new or existing procedures in a project-specific focused approach. The Investigators consult with the MCL director to define goals of the research and molecular tesl.ing options that best serve the project. This individualized attention and professional expertise affords a substantial economy of service from this shared resource to Cancer Center members and other Washington University School of Medicine researchers. With the rapid advancement of the understanding of the genetic basis of common neoplasias, the availability of expert research support for clinical studies will serve to expedite assessment of genetic markers and to rapidly translate research findings to clinical tools. The MCL is also a resource of key equipment for molecular genetic research available for supervised shared use. Molecular test development and fees are configured with the investigator per collaborative project with a chargeback system to reimburse the MCL for project-specific reagents and services. Many research projects supported by the MCL have resulted in translation of the findings to new clinical lab tests for patients at SCC and referred from other US centers. Test validation to clinical application is uniquely achieved through the interface with the personnel and facilities of the adjoining Clinical Molecular Diagnostic Laboratory facility [CAP & CLIA-certified], also directed by Barbara A. Zehnbauer, Ph.D.

$iteman癌症中心的分子核心实验室(MCL)是一个共享的资源设施，为基础研究和临床研究提供分子病理学服务。MCL的使命是迅速将基础研究观察转化为新的诊断和/或预后临床分子测试。MCL与研究人员合作开发和实施分子生物学方法来分析人类恶性肿瘤中的突变和异常表达，MCL使用的方法范围从常规的(基因组Southern分析、PCR筛选、DNA测序)到项目特定的技术(BAC探针、蛋白质截断测试、端粒长度)。新项目往往需要采用针对具体项目的方法，对新的或现有的程序进行调整和优化。研究人员与MCL主任协商，以确定研究的目标和最好地为项目服务的分子测试选项。这种个性化的关注和专业知识从这一共享资源中为癌症中心成员和华盛顿大学医学院的其他研究人员提供了大量经济服务。随着对常见肿瘤遗传基础认识的快速发展，为临床研究提供专家研究支持将有助于加快对遗传标记的评估，并迅速将研究成果转化为临床工具。MCL也是分子遗传学研究的关键设备资源，可供监督共享使用。分子测试的开发和费用由研究人员为每个合作项目配置，并具有按存储容量使用计费系统，以补偿MCL用于项目特定试剂和服务的费用。多项研究项目获 MCL已经将这些发现转化为SCC患者的新临床实验室测试，并从其他美国中心转介。临床应用的测试验证是通过与毗邻的临床分子诊断实验室[CAP&CLIA认证]的人员和设施接口实现的，该实验室也由Barbara A.Zehnbauer博士指导。